Chimerix unrolls early win for glioma drug picked up earlier this year in acquisition
Small biotech Chimerix made a big bet early this year when it bought out Oncoceutics and lead drug ONC201 for gliomas. Now, that investment is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
